Sign in

    Carlyle Group Inc (CG)

    You might also like

    The Carlyle Group Inc. (NASDAQ: CG) is a global investment firm that manages private capital across various asset classes. The company advises funds and vehicles in private equity, credit, and investment solutions, offering services such as fund management, transaction advisory, and oversight. Carlyle operates through three main business segments, each contributing to its diverse portfolio of investment strategies and solutions.

    1. Global Private Equity - Advises buyout, middle market, and growth capital funds, as well as real estate, infrastructure, and natural resources funds. Includes NGP Carry Funds focused on energy and natural resources.

    2. Global Credit - Manages funds and vehicles focused on loans, structured credit, direct lending, distressed credit, infrastructure debt, and insurance solutions. Also includes aircraft financing and global capital markets activities.

    3. Global Investment Solutions - Advises private equity programs and supports co-investment and secondary market activities.

    NamePositionExternal RolesShort Bio

    Harvey M. Schwartz

    ExecutiveBoard

    Chief Executive Officer (CEO)

    • Group Chairperson and Non-Executive Director of The Bank of London<br>- Board Member of SoFi Technologies, Inc.<br>- Board Member of One Mind

    Former President and Co-COO of Goldman Sachs; joined CG in 2023 and has driven strong financial results and strategic growth.

    View Report →

    Christopher Finn

    Executive

    Chief Operating Officer (COO)

    None

    Joined CG in 1996; retiring as COO effective 2024-06-30; has played a key role in global operations and fund management.

    Jeffrey W. Ferguson

    Executive

    General Counsel

    None

    Joined CG in 1999; leads legal and compliance functions; previously worked at Latham & Watkins and Vinson & Elkins.

    Lindsay LoBue

    Executive

    Chief Operating Officer (COO)

    • Board Member of Enel Finance Americas<br>- Member of the Board of Regents at Boston College

    Joined CG in 2023; promoted to COO in 2024; previously spent over 20 years at Goldman Sachs, specializing in credit products and strategic growth initiatives.

    Afsaneh Beschloss

    Board

    Director

    • Founder and CEO of RockCreek<br>- Trustee of the Rockefeller Foundation and Georgetown University

    Rejoined CG's Board in 2024; former Managing Director at CG; extensive experience in sustainable investing and global finance.

    Daniel A. D’Aniello

    Board

    Co-Founder and Chairman Emeritus

    • Chairman of the American Enterprise Institute<br>- Co-Chairman of the Institute for Veterans and Military Families<br>- Trustee of Syracuse University

    Co-founded CG in 1987; served as Chairman until 2018; key figure in CG's operational and strategic development.

    David M. Rubenstein

    Board

    Co-Founder and Co-Chairman

    • Chairman of multiple organizations, including the Kennedy Center, Council on Foreign Relations, and National Gallery of Art<br>- Board Member of Johns Hopkins Medicine and others

    Co-founded CG in 1987; former Co-CEO; influential in CG's global expansion and philanthropic initiatives.

    Derica W. Rice

    Board

    Director

    • Board Member at Bristol-Myers Squibb, Target Corporation, and The Walt Disney Company

    Joined CG's Board in 2021; former CFO of Eli Lilly and President of CVS Caremark; extensive experience in finance and healthcare.

    Lawton W. Fitt

    Board

    Lead Independent Director

    • Director at Ciena Corporation and The Progressive Corporation<br>- Trustee of several organizations

    Joined CG's Board in 2012; Chair of the Nominating and Corporate Governance Committee; extensive experience in investment banking and governance.

    Linda H. Filler

    Board

    Director

    • Lead Independent Director at Danaher Corporation<br>- Chair of Veralto Corporation<br>- Board Member at Eversight

    Appointed to CG's Board in 2022; serves as Sustainability Lead and member of the Nominating and Corporate Governance Committee.

    Mark S. Ordan

    Board

    Director

    • Non-Executive Chair of Pediatrix Medical Group<br>- Chair of the U.S. Chamber of Commerce<br>- Board Member of Vassar College

    Appointed to CG's Board in 2022; extensive leadership experience as CEO of multiple companies, including Sunrise Senior Living and Washington Prime Group.

    Sharda Cherwoo

    Board

    Director

    • Board Member at World Kinect Corporation and Tax Analysts<br>- Executive in Residence at Columbia Business School

    Appointed to CG's Board in 2023; nearly 40 years at EY, specializing in digital transformation and private equity advisory.

    William E. Conway, Jr.

    Board

    Co-Founder and Co-Chairman

    • Former Chairman of Johns Hopkins Medicine<br>- Former Vice Chairman of Catholic University of America

    Co-founded CG in 1987; served as interim CEO in 2022-2023; instrumental in CG's growth and investment strategy.

    1. Despite significant improvements in FRE margins this year, what specific steps do you plan to take to further enhance the FRE margin in 2025, and how much more incremental margin expansion is realistically achievable?
    2. Given the modest 2% year-on-year growth in management fees, even with increased AUM, how do you reconcile this with the momentum you've highlighted, and is there a clear path to achieving double-digit management fee growth as you deploy more capital?
    3. With the potential for aggressive trade policies like tariffs under the Trump administration, how have you scenario-tested the impact on your global investment strategy and portfolio companies, particularly in regions like Europe and Japan?
    4. While you've had some notable exits like StandardAero and Rigaku, the net IRR in key buyout funds remains underwhelming, with CP VII at 8% and CEP V declining to 4%; how do you plan to address these performance challenges, and do you expect this to affect future fundraising?
    5. Year-to-date fundraising appears to be lagging behind your $40 billion target, with around $26 billion raised so far; can you clarify whether you still expect to meet this goal in the current quarter, and what are the main drivers or hurdles influencing this?
    Program DetailsProgram 1Program 2Program 3Program 4
    Approval DateFebruary 2021 October 2021 February 2023 February 6, 2024
    End Date/DurationNo specified end date No specified end date No specified end date No specified end date
    Total Additional Amount$500 million Reset to $500 million Reset to $500 million Reset to $1.4 billion
    Remaining Amount$0 $0 $0 $928 million
    DetailsCan be suspended or discontinued at any time Can be suspended or discontinued at any time Can be suspended or discontinued at any time Can be suspended or discontinued at any time; includes repurchases for tax withholding on equity awards

    Notable M&A activity and strategic investments in the past 3 years.

    CompanyYearDetails

    Carlyle Aviation Partners

    2023

    Acquisition included an earn-out of up to $150 million based on revenue and earnings targets from 2020 to 2025, with a termination and settlement agreement in Q1 2023 that resulted in a $68.6 million payment (plus additional installments scheduled for 2024 and 2025) and prior payments totaling $53.6 million.

    Abingworth LLP

    2022

    Acquired on August 1, 2022 to expand Carlyle’s healthcare platform, adding over $2 billion in assets under management and a specialized team, with a base purchase price of $185.6 million (including a $25 million equity component) and potential future incentive payments of up to $130 million plus performance revenue rights.

    CBAM Partners LLC

    2022

    Completed on March 21, 2022, the acquisition of management contracts for $812.9 million involved $618.4 million in cash and approximately 4.2 million newly issued shares, integrating a portfolio with $15 billion in assets under management in U.S. and European CLOs, along with CLO notes valued at $175.9 million.

    iStar Triple Net Lease Portfolio

    2022

    Acquired in March 2022 with an enterprise value of $3 billion, the deal was funded with $2 billion in debt and $1 billion in equity (including a $200 million balance sheet investment by Carlyle), and involved a portfolio spanning 18.3 million square feet across diverse US properties, aimed at scaling the real estate credit platform to a $10 billion AUM strategy.

    No recent press releases or 8-K filings found for CG.